Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

173.52 -0.27 (-0.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
48 49 Next >
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Recap: Biogen Q1 Earnings
Biogen (NASDAQ:BIIB) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Via Benzinga
Earnings Preview For Biogen
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an... 
Via Benzinga
Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator
Via Benzinga
Why Biogen Stock Looks 'Too Good To Ignore,' According To One Analyst
Biogen stock could see a resurgence later this year, according to one analyst. 
Via Investor's Business Daily
Bear Of The Day: Biogen
Biogen’s MS revenues were $1.79 billion in the reporter quarter, including Ocrevus royalties, which declined 1% (both actual and constant currency basis) year over year. 
Via Talk Markets
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
3 Undervalued Stocks to Buy This Week
Here are the three undervalued stocks to buy this week. 
Via Talk Markets
If You Invested $100 In Biogen 15 Years Ago, Here's How Much You Would Have Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.88% on an annualized basis producing an average annual return of 11.31%. Currently, Biogen has a market capitalization of... 
Via Benzinga
Analyst Ratings for Biogen
Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Biogen Earnings Conference Call Is Coming Up, Here's What You Need To Know
Biogen (NASDAQ:BIIB) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
Why This Analyst Believes Biogen Is 'Too Good to Ignore'
Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Upgrades 
Via Benzinga
Biogen’s Aduhelm Crashes the Biotech Sector
Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock. 
Via InvestorPlace
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
Via InvestorPlace
Friday Stocks Update
Royal Dutch Shell rose again on its earnings but is still at a p/e ratio of under 11x earnings. 
Via Talk Markets
How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug
Only Medicare patients enrolled in specific studies will receive reimbursement. 
Via Investor's Business Daily
Why Is Trevi Therapeutics (TRVI) Stock On the Move Today?
Trevi Therapeutics (TRVI) stock is slipping on Friday but that's only after the biopharmaceutical company saw a massive rally yesterday. 
Via InvestorPlace
Why Is Biogen (BIIB) Stock in the Spotlight Today?
Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today. 
Via InvestorPlace
Morning Brief: Top Stories Dominating Financial Media on Friday, April 8
Reuters Blockchain-Based Online Games Like Axie Infinity Continue To Hook Users Despite Risks Blockchain-based online games like Axie Infinity, dubbed “play-to-earn,... 
Via Benzinga
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes
Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:& 
Via Benzinga
Keep Eyes on Momentum in the Small-Cap Index and The Biotech Space
If BIIB can clear and close over roughly $212, it would confirm that price and momentum agree and show it's potentially ready for another move higher. 
Via Talk Markets
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week. 
Via Investor's Business Daily
Biogen Inc. (NASDAQ:BIIB) Investor Notice: Deadline in Lawsuit on April 8, 2022
San Diego, CA -- (SBWIRE) -- 03/28/2022 -- The Shareholders Foundation announced that a deadline is coming up on April 8, 2022 in the lawsuit filed for certain investors of Biogen Inc. (NASDAQ:BIIB). 
Via SBWire
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have  
Via Benzinga
Why I Sold Kohl’s Corporation Despite Possible Buyout Deal
2022 has been a headline-packed for Kohl’s and KSS stock. But after a closer look at my portfolio grader, this is why it was time to sell. 
Via InvestorPlace
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.